Posttherapeutic biomarker expression in mCRC patients with liver metastasis” The PRO-MARKER observational study

Posttherapeutic biomarker expression in mCRC patients with liver metastasis” The PRO-MARKER observational study - PRO-MARKER

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00030593

Enrollment

100

Registered

2023-07-28

Start date

2023-11-15

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C19 C78

Interventions

Group 1: As this is an observational study only there are no additional risks for the patient. The treatment is chosen individually for the patient and takes place independently of the study presented

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: • Histologically proven mCRC • Patients with liver dominant metastatic CRC • Inclusion after full resection or local ablation of liver metastases • ECOG 0-2 • Limited extrahepatic metastases

Exclusion criteria

Exclusion criteria: • Life expectancy =3 months • Known liver cirrhosis

Design outcomes

Primary

Measure	Time frame
Biomarker development (ctDNA) after local therapy or locoregional therapy regimen.	—

Secondary

Measure	Time frame
Progression free survival as determined by HBI MRI of the liver and CT Thorax & Abdomen	—

Countries

Germany

Contacts

Public ContactJens Ricke

LMU München Klinik und Poliklinik für Radiologie

jens.ricke@med.uni-muenchen.de+4989440076642

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026